Immunopharmacology of the immunotherapy of cancer, infection, and autoimmunity.

Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Immunopharmacology of the immunotherapy of cancer, infection, and autoimmunity.

Fundam Clin Pharmacol. 1987;1(4):283-96. Unique Identifier : AIDSLINE MED/88138232
Hadden JW; Program of Immunopharmacology, University of South Florida; Medical College, Tampa 33612.

Abstract: The current status and future prospects of the immunotherapy of cancer, infection, and autoimmunity are reviewed briefly. Progress in treating the immunodeficiency of cancer with thymic hormones and drugs such as levamisole and lentinan has produced some degree of remission stabilization. Interferon, interleukin II, and LAK cells have inhibited active, progressive cancer. New approaches with monoclonal antibodies, immunotoxins, tumor necrosis factors, and so on are under rapid development. Future prospects focus on combined approaches yielding synergy. Treatment of infections in animals and man either prophylactically or therapeutically, with thymic hormones, interferons, and thymomimetic drugs such as levamisole and isoprinosine, demonstrate the efficacy of this approach. The use of these agents in conjunction with antimicrobial therapy in immunosuppressed hosts is warranted. In immunodeficiency associated with AIDS virus infection, interleukin II, thymic hormones, isoprinosine, and imuthiol have shown effect in partially restoring immune function, although with little clinical benefit. Their use with antiviral therapy is advocated. Finally, thymic hormones, isoprinosine, levamisole, and other sulfur-containing compounds have ameliorated murine and human autoimmune disease presumably through effects in improving cellular immune function. Continued development of this type of therapy is warranted. The continued progress of immunopharmacology as the science of immunotherapy portends the future successful development of many therapeutic approaches to these diseases.

Keywords: Adjuvants, Immunologic/*THERAPEUTIC USE Autoimmune Diseases/*THERAPY *Immunotherapy Infection/*THERAPY Neoplasms/*THERAPY JOURNAL ARTICLE

880630
M8860491

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .